ea0034p37 | Clinical biochemistry | SFEBES2014
Alshehri Abdulrahman
, Ross Richard
, Wilkinson Ian
Rationale: Over the last 20 years, granulocyte colony-stimulating factor (GCSF) has become a recognized therapy in the treatment of patients suffering from neutropenia. Current therapies require daily injections of GCSF to stimulate stem cell production and response to treatment is often unpredictable as GCSF is rapidly cleared. A number of approaches to reducing GCSF clearance have been tried mainly through conjugation with another moiety. The technologies already being emplo...